Mycoplasma genitalium

Image

About Mycoplasma genitalium

  • Caused by the bacteria Mycoplasma genitalium, genitalium (also often referred to as MG) is a non-notifiable STI .
  • Many M. genitalium cases are asymptomatic. When present, signs and symptoms are similar to those of chlamydia infection.1
  • Persistent infection due to treatment failure is common, due to increases in antimicrobial resistance.1
  • M. genitalium is an established cause of PID, urethritis and cervicitis.

Diagnosis and treatment

  • Screening for asymptomatic M. genitalium infection is not recommended, aside from sexual contacts of a confirmed case.2
  • Nucleic acid amplification testing on high vaginal swab for women. First pass urine specimen for men, or where a self-collected vaginal or endocervical swab cannot be taken.1,3
  • When possible, test for macrolide resistance mutations and treat accordingly. See the Australian STI management guidelines for further information about treatment options. 

Follow-up and management

  • Test of cure should be undertaken 14-21 days after completion of treatment, only when there are ongoing symptoms and/or risk of reinfection or sequalae.3
  • It is recommended that ongoing sexual partners of the index case are tested and treated. The time period for contact tracing is currently unknown.1

 

For more information about Mycoplasma genitalium, see:

Australian STI Management Guidelines: Mycoplasma genitalium

References

References

  1. Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine. Australasian Contact Tracing Guidelines 2016 [updated 2016; cited 2022 16th June]. Available from: http://contacttracing.ashm.org.au/
  2. Melbourne Sexual Health Centre. Treatment Guidelines [updated July 2021; cited 2022 16th June]. Available from: https://www.mshc.org.au/health-professionals/treatment-guidelines/mycoplasma-genitalium-treatment-guidelines
  3. Australasian Sexual Health Alliance. Australian STI Management Guidelines for use in Primary Care 2018 [updated December 2021; cited 2022 16th June]. Available from: https://sti.guidelines.org.au/

MoCCA is funded by the National Health and Medical Research Council (APP1150014) and is a collaboration between the University of Melbourne and our project investigators and partner organisations in Victoria, New South Wales and Queensland. Click here for a list of our collaborators.

We acknowledge and pay respect to the Traditional Owners of the lands upon which this research is being conducted.

uomlogo